Alembic Pharmaceuticals said the warning letter relates to a clinical investigator involved in a study carried out at Alembic’s bioequivalence facility in Vadodara. The company became aware of the communication on July 12.
Alembic Pharmaceuticals said the warning letter relates to a clinical investigator involved in a study carried out at Alembic’s bioequivalence facility in Vadodara. The company became aware of the communication on July 12.